Quick Answer
PMV Pharmaceuticals, Inc. reported Net Income Loss of -$77.74 million for the year ending 2025.
- PMV Pharmaceuticals, Inc. showed a decrease of -32.4% in Net Income Loss from 2024 to 2025.
- This data is from PMV Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on March 6, 2026.
- XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2019: -$6.00 million | Q2 2019: -$6.13 million | Q3 2019: -$6.18 million | Q1 2020: -$7.26 million | Q2 2020: -$7.97 million | Q3 2020: -$8.76 million | Q1 2021: -$11.60 million | Q2 2021: -$12.87 million | Q3 2021: -$15.01 million | Q1 2022: -$18.43 million | Q2 2022: -$17.31 million | Q3 2022: -$18.23 million | Q1 2023: -$19.13 million | Q2 2023: -$17.44 million | Q3 2023: -$16.64 million | Q1 2024: -$15.27 million | Q2 2024: -$1.21 million | Q3 2024: -$19.23 million | Q1 2025: -$17.44 million | Q2 2025: -$21.21 million | Q3 2025: -$21.06 million.
- Over the full 8 years of available data (2018 to 2025), PMV Pharmaceuticals, Inc.'s Net Income Loss has declined by 343.3%.
- Historical annual values: Fiscal year 2025: -$77.74 million | Fiscal year 2024: -$58.71 million | Fiscal year 2023: -$68.96 million | Fiscal year 2022: -$73.32 million | Fiscal year 2021: -$57.85 million | Fiscal year 2020: -$34.44 million | Fiscal year 2019: -$25.35 million | Fiscal year 2018: -$17.54 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: